4.7 Article

Heritability and genetic variance of dementia with Lewy bodies

Journal

NEUROBIOLOGY OF DISEASE
Volume 127, Issue -, Pages 492-501

Publisher

ACADEMIC PRESS INC ELSEVIER SCIENCE
DOI: 10.1016/j.nbd.2019.04.004

Keywords

Genetic variance; Dementia; Lewy bodies; Genetic correlation

Categories

Funding

  1. Alzheimer's Society
  2. Lewy Body Society
  3. National Institutes of Neurological Disease and Stroke
  4. Neuroscience Research Australia
  5. University of New South Wales - South West Dementia Brain Bank
  6. BRACE (Bristol Research into Alzheimer's and Care of the Elderly)
  7. Brains for Dementia Research
  8. Medical Research Council [MR/N026004/1]
  9. Medical Research Council (MRC)
  10. Brains for Dementia Research (BDR) (Alzheimer Society)
  11. Autistica UK
  12. NIHR Oxford Biomedical Research Centre - Wellcome Trust
  13. Canadian Consortium on Neurodegeneration in Aging
  14. CERCA Programme/Generalitat de Catalunya
  15. ARUK
  16. Big Lottery Fund
  17. Taub Institute
  18. Panasci Fund
  19. Parkinson's Disease Foundation
  20. NIH [AG05131]
  21. Michael J. Fox Foundation for Parkinson's Research, NINDS R01 [NS078086]
  22. Mayo Clinic Jacksonville is a Morris K. Udall Parkinson's Disease Research Center of Excellence (NINDS) [NS072187]
  23. Little Family Foundation
  24. Mangurian Foundation Program for Lewy Body Dementia
  25. Alzheimer's disease Research Center [P50 AG016547]
  26. Mayo Clinic Rochester
  27. National Institute on Aging [P50 AG016574, U01 AG006786]
  28. Queen Square Brain Bank at the UCL Institute of Neurology - ARUK senior fellowship
  29. MRC London Neurodegenerative Diseases Brain Bank
  30. Brains for Dementia Research project - Alzheimer's Society
  31. (ARUK)
  32. NIHR UCLH Biomedical Research Centre
  33. Queen Square Dementia Biomedical Research Unit
  34. Intramural Research Program of the National Institute on Aging, National Institutes of Health, Department of Health and Human Services [AG000951-12]
  35. Penn Alzheimer's Disease Core Center [AG10124]
  36. Penn Morris K. Udall Parkinson's Disease Research Center [NS053488]
  37. French program Investissements d'avenir [ANR-10-IAIHU-06]
  38. Helsinki University Central Hospital
  39. Folkhalsan Research Foundation
  40. Finnish Academy
  41. National Institutes of Health [R01NS037167, R01CA141668, P50NS071674]
  42. University of Wisconsin Transdisciplinary Tobacco Use Research Center [P50 DA019706, P50 CA084724]
  43. Intramural Research Program of the National Institutes of Health (National Institute of Neurological Disorders and Stroke) [ZIA NS003154]
  44. Johns Hopkins Morris K. Udall Center of Excellence for Parkinson's Disease Research [NIH P50 NS38377]
  45. Johns Hopkins Alzheimer's disease Research Center [NIH P50 AG05146]
  46. Canadian Institute for Health Research
  47. Krembil Foundation
  48. Babcock Memorial Trust
  49. Ann Arbor Veterans Affairs Hospital
  50. International Genomics of Alzheimer's Project (IGAP) - French National Foundation on Alzheimer's disease and related disorders
  51. LABEX (laboratory of excellence program investment for the future) DISTALZ grant
  52. Inserm
  53. Institut Pasteur de Lille, Universite de Lille 2
  54. Lille University Hospital
  55. Alzheimer's Research UK [503176]
  56. Wellcome Trust [076113, 085475, 090355]
  57. German Federal Ministry of Education and Research (BMBF): Competence Network Dementia (CND) [01GI0102, 01GI0711, 01GI0420]
  58. NIH/NIA [U01 AG032984, U24 AG021886, U01 AG016976]
  59. AGES [N01-AG-12100]
  60. NHLBI [R01 HL105756]
  61. Icelandic Heart Association
  62. Erasmus Medical Center and Erasmus University
  63. Alzheimer's Association [ADGC-10-196728]
  64. Intramural Research Programs of the National Institute of Neurological Disorders and Stroke (NINDS)
  65. National Institute on Aging (NIA)
  66. National Institute of Environmental Health Sciences
  67. National Institutes of Health, Department of Health and Human Services [1ZIA-NS003154, Z01-AG000949-02, Z01-ES101986]
  68. Department of Defense [W81XWH-09-2-0128]
  69. Michael J Fox Foundation for Parkinson's Research
  70. American Parkinson's disease Association (APDA)
  71. Barnes Jewish Hospital Foundation
  72. Greater St Louis Chapter of the APDA
  73. Hersenstichting Nederland
  74. Prinses Beatrix Fonds
  75. KORA (Cooperative Research in the Region of Augsburg)
  76. Forschungszentrum fur Umwelt and Gesundheit - German Federal Ministry of Education, Science, Research
  77. State of Bavaria - National Genome Research Network (NGFNplus) [01GS08134]
  78. (German Federal Ministry for Education and Research)
  79. German Federal Ministry of Education and Research [NGFN 01GR0468]
  80. (PopGen) [01EW0908]
  81. EU Joint Programme Neurodegenerative Diseases Research (JPND) project under the aegis of JPND
  82. BMBF [01ED1406]
  83. iMed - the Helmholtz Initiative on Personalized Medicine
  84. French National Agency of Research [ANR-08-MNP-012]
  85. France-Parkinson Association
  86. Assistance Publique-Hopitaux de Paris (PHRC) [AOR-08010]
  87. Landspitali University Hospital Research Fund
  88. Icelandic Research Council
  89. European Community Framework Programme 7, People Programme
  90. IAPP on novel genetic and phenotypic markers of Parkinson's disease and Essential Tremor (MarkMD) [PIAP-GA-2008-230596]
  91. Michael J. Fox Foundation
  92. (Biomedicum, University of Helsinki)
  93. UK replication cases on ImmunoChip
  94. WTCCC2 project - Wellcome Trust [083948/Z/07/Z, WTCCC1]
  95. Wellcome Trust disease centre [WT089698/Z/09/Z]
  96. Parkinson's UK [8047, J-0804]
  97. Michael J Fox Foundation
  98. Department of Health's National Institute for Health Research Biomedical Research Centres
  99. Wellcome Trust/Medical Research Council Joint Call in Neurodegeneration award [WT089698]
  100. Medical Research Council Protein Phosphorylation Unit at the University of Dundee
  101. National Institute on Aging, NIH, Bethesda, MD, USA
  102. University of California Healthcare
  103. MRC [UKDRI-1009, G0701075, MR/L016397/1, G1001799, MR/N026004/1, MR/L023784/2, G0901254, G1001253, MR/L022656/1, MR/J004758/1, G1100540, MR/K01417X/1, UKDRI-3003, G0400074, G0502157, G0900652] Funding Source: UKRI
  104. Alzheimers Research UK [ARUK-PhD2014-16, ART-PPG2009A-1, ART-PG2010-1, ART-PPG2011A-14] Funding Source: researchfish
  105. Medical Research Council [UKDRI-1009, G1001253, MR/L501542/1, G0901254, G0701075, MR/N026004/1, MR/K01417X/1, MR/J004758/1] Funding Source: researchfish
  106. Parkinson's UK [J-0804, G-1307] Funding Source: researchfish
  107. Rosetrees Trust [M733] Funding Source: researchfish
  108. NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [ZIANS003154] Funding Source: NIH RePORTER
  109. NATIONAL INSTITUTE ON AGING [ZIAAG000936] Funding Source: NIH RePORTER

Ask authors/readers for more resources

Recent large-scale genetic studies have allowed for the first glimpse of the effects of common genetic variability in dementia with Lewy bodies (DLB), identifying risk variants with appreciable effect sizes. However, it is currently well established that a substantial portion of the genetic heritable component of complex traits is not captured by genome-wide significant SNPs. To overcome this issue, we have estimated the proportion of phenotypic variance explained by genetic variability (SNP heritability) in DLB using a method that is unbiased by allele frequency or linkage disequilibrium properties of the underlying variants. This shows that the heritability of DLB is nearly twice as high as previous estimates based on common variants only (31% vs 59.9%). We also determine the amount of phenotypic variance in DLB that can be explained by recent polygenic risk scores from either Parkinson's disease (PD) or Alzheimer's disease (AD), and show that, despite being highly significant, they explain a low amount of variance. Additionally, to identify pleiotropic events that might improve our understanding of the disease, we performed genetic correlation analyses of DLB with over 200 diseases and biomedically relevant traits. Our data shows that DLB has a positive correlation with education phenotypes, which is opposite to what occurs in AD. Overall, our data suggests that novel genetic risk factors for DLB should be identified by larger GWAS and these are likely to be independent from known AD and PD risk variants.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available